BOI Bank Irel13.375

RNS Number:6672C
Biotrace International PLC
16 December 1999


               BIOTRACE INTERNATIONAL PLC
                            
              ACTION SATISFACTORILY SETTLED
                            
Biotrace International Plc, leader in the manufacture and
marketing   of   rapid  response  systems   for   hygiene
cleanliness  and microbial detection, is  today  able  to
announce  that  the court case brought against  it  by  a
former chief executive has been settled.

As announced by Biotrace earlier this year, Brian Levett,
chief  executive  officer of Biotrace  between  1991  and
1995,  attempted to bring an action against Biotrace  for
#1.3 million damages plus costs.  The action is based  on
the  assumption  that  Mr  Levett  could  have  sold  his
1,761,363 shares in Biotrace, which he acquired upon  the
exercise of his options, at a price of 120p, rather  than
55p at which they were sold on 7th May 1999.

Following  an  interlocutory  decision  by  the   Bristol
Mercantile  Court,  which limited Mr  Levett's  claim  in
damages  to  an  attempted  exercise  of  500,000   share
options,  he  has been prevented from claiming  the  full
#1.3  million  of damages in respect of  the  balance  of
1,261,363 share options.  Mr Levett has agreed to  accept
a  payment  of  #350,000, the amount made into  court  by
Biotrace  in October when the action was brought  against
the Company.

With  regard  to  Mr Levett's resultant claim  to  costs,
Biotrace  has agreed to a compromise and will  contribute
#28,000 to Mr Levett's total costs.

For further information:
Biotrace  International             

Ian Johnson, Chief Executive Officer
Peter Morgan, Finance Director
Tel:  +44  (0)1656 641 400

Buchanan Communications         
Nicola How
Tel: +44 (0) 171 466 5000


END
MSCCCACBQDDDFBD

Bank Irel13.375 (LSE:BOI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Bank Irel13.375 (LSE:BOI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024